Ask the expert
ERKNet, the European Reference Network for Rare Kidney Diseases, wants to offer the exceptional expertise of its internationally renowned specialists to European patients affected by rare kidney diseases and their families.
ERKNet, the European Reference Network for Rare Kidney Diseases, wants to offer the exceptional expertise of its internationally renowned specialists to European patients affected by rare kidney diseases and their families.
World Pulmonary Hypertension Day is an annual event celebrated around the globe to raise awareness about Pulmonary Hypertension (PH), a grave disease that affects the lungs and the heart.
The next 2 to 5 May will be held at the WTC in Barcelona the XXVI annual meeting of the Catalan society of neurology.
Data from the clinical study HYPER-H21-3 show that the treatment with Dehydra TECH-CBD led to a decrease in pulmonary arterial pressure in healthy volunteers who were exposed to low levels of oxygen, conditions that replicated pulmonary hypertension (PH). This treatment, still under research, from Lexaria Bioscience is derived from cannabis and is used to treat PH.
Volem agrair-te que formis part d'aquest projecte comú. Perquè gràcies a tu i a les milers de persones que, com la teva realitzen un donatiu, col·laboreu amb Esclerosi Tuberosa a treballar cada dia.
The final results of the BREEZE study say that Tyvaso DPI, a dry powder formulation of vasodilator treprostinil under research, is safe, effective, and more comfortable than the Tyvaso nebulizer (inhaled treprostinil) approved for people with pulmonary arterial hypertension (PAH).
El passat 20 de maig es va realitzar la primera carrera.
In ASEM Catalunya we are very happy about one of our activities, the Choir. This group of music and singing lovers meets up every Monday from 10 a.m. to 11:30 a.m. in Fabra i Coats under Joaquín’s orders, the group’s new head.
Down below you will the interview featured in issue 55 of Lligam with Sant Joan de Déu Hospital’s neuro-paediatrician, Daniel Natera.
5 d'octubre del 2021: JCR Pharmaceuticals Co, Ltd (TSE 4552; president: Shin Ashida; "JCR") ha anunciat que l'Administració d'Aliments i Medicaments dels EUA (FDA) va atorgar la designació de Via Ràpida al medicament en investigació.